

No. 6-3/BD/107/04-DC(REREG2010)

From :
The Drugs Controller General (India)
Directorate General of Health Services

FDA Bhawan, New Delhi
Dated

18 AUG 2011

To,

M/S. Ethachem,
107, Marine Chambers, 11 New Marine Lines
Mumbai 400020

Sub: -Registration of M/S. ZHEJIANG MEDICINE CO LIMITED XINCHANG PHARMACEUTICAL FACTORY OF NO.98 EAST XINCHANG DADAO ROAD XINCHANG,ZHEJIANG 312500,P.R CHINA under the Provisions of Drug & Cosmetics Rules for the purpose of import of drugs in India

Dear Sir,

Please refer to your application no. MIL dated 04/03/2011, received by this Office vide diary no. 29855 dated 21/06/2011 on the above subject. Registration Certificate in Form 41 under the Rules is issued for the manufacturing site along with the name (s) of drug (s) imported under the said Certificate subject to the condition:

1. The drugs shall conform to the standards / specifications mentioned in the Second Schedule of the Act, or such other standards / specifications forwarded by you and approved by this Directorate.
2. The drugs shall have the composition, strengths, standards and packing as approved by this Directorate.
3. Dispute, if any, in respect of the payment of fees and submission of TR6 challan, shall have to be settled between the bank and the applicant.
4. The drugs will be required to be withdrawn from sale from the market in case any undesirable reactions due to its medication are brought to light at any stage. This Directorate should be informed of adverse reports on the drug, if any.
5. The drugs shall be marketed for indications for which they have been approved.
6. If any claim is made for these drugs in future other than those approved, prior permissions from this Directorate will be necessary before such claim is made.
7. The drugs shall be supplied and marketed as per the provisions of the existing Drugs & Cosmetics Act and Rules thereunder.

8. This registration in no way relieves you of the responsibility of complying with all other provisions of the Drugs & Cosmetics Act and Rules there under, and any other provisions of any other Act and Rules applicable in the matter concerned.
9. Each consignment of the drugs to be imported by you shall be accompanied by a test / analysis reports.
10. Based on this registration, import applications for the drug (s) endorsed in the enclosed Registration Certificate shall be considered for the issue of Form 10 Licence under the Rules.
11. This Registration Certificate is being issued under the condition that during the pendency of Registration, the applicant may be required to deposit inspection fee as stipulated under Clause (5) of Rule 24-A and enable inspection of manufacturing site by the officials authorised for this purpose. Non-compliance to this condition as and when so directed would result in cancellation of Registration Certification.
12. **ANNUAL PRODUCT REVIEW DATA OF TWO YEARS OF PRODUCT BY MANUFACTURER SHALL BE SUBMITTED TO THIS OFFICE .**

Please note that Registration Certificate issued is liable to be suspended / cancelled, if any of the condition stipulated above is not complied with, apart from any other condition that may be taken under the provisions of the Drugs & Cosmetics Act, 1940 and the Rules there under.


Please acknowledge the receipt.

Yours faithfully,


Drugs Controller General (India)

Copy forwarded to:

13. The Assistant Drug Controller (I), New Custom House, Annexe, Ballard Estate, Fort, Mumbai-400038.
14. The Assistant Drug Controller (I), 15/1, Strand Road, Custom House, Kolkata-700001.
15. The Assistant Drug Controller (I), Room No. 66, 2nd Floor, Custom House, Chennai-600001.
16. The Assistant Drug Controller (I), Jawaharlal Nehru Port, Trust Nhava Seva Port, Raigard, Maharashtra.
17. The Assistant Drug Controller (I), International Air Cargo Complex, Indira Gandhi International Air Port, New Delhi-110037.



सत्यमेव जयते

GOVERNMENT OF INDIA

Central Drugs Standard Control Organisation

Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)

Form 41

(See Rule 27-A)

REGISTRATION CERTIFICATE

Registration Certificate issued for import of drugs into India

Under Drugs and Cosmetics Rules, 1945

Registration Certificate No. BD-488

Dated

- M/S. ZHEJIANG MEDICINE CO LIMITED XINCHANG PHARMACEUTICAL FACTORY OF NO.98 EAST XINCHANG DADAO ROAD XINCHANG,ZHEJIANG 312500,P.R CHINA having factory premises at M/s./ZHEJIANG MEDICINE CO LIMITED XINCHANG PHARMACEUTICAL FACTORY OF NO.98 EAST XINCHANG DADAO ROAD XINCHANG,ZHEJIANG 312500,P.R.CHINA has been registered under Rule 27-A as a manufacturer and is hereby issued this Registration Certificate.
- Name(s) of drug(s), which may be imported under this Registration Certificate (Please refer the enclosed list of drugs).
- This Registration Certificate shall be in force from 01/12/2010 to 30/11/2013 unless it is sooner suspended or cancelled under the rules.
- This Registration Certificate is issued through the office of the manufacturer or his authorised agent in India M/S. Ethachem, 107, Marine Chambers, 11 New Marine Lines Mumbai 400020 who will be responsible for the business activities of the manufacturer in India in all respects.
- This Registration Certificate is subject to the conditions stated overleaf and to such other conditions as may be specified in the Act and the Rules, from time to time.

Place: New Delhi

Date: 18 AUG 2011




LICENSING AUTHORITY

डॉ. सुरिंदर सिंह
Dr. SURINDER SINGH
औषधि नियंत्रक (भारत) / Drugs Controller (India)
स्वास्थ्य सेवा महानिदेशालय
Dta. General of Health Services
FDA Bhawan, Kolla Road,
New Delhi-110002

Conditions of the Registration Certificate

1. The Registration Certificate shall be displayed at a prominent place by the authorised agent.
2. No drug shall be registered unless it has a free sale approval in the country of origin, and/or in other major countries.
3. The manufacturer or his authorised agent in India shall comply with the conditions of the import licence issued under the Drugs and Cosmetics Rules, 1945.
4. The manufacturer or his authorised agent in India shall inform the licensing authority forthwith in the event of any administrative action taken due to adverse reaction, viz. market withdrawal, regulatory restrictions, or cancellation of authorisation, and/or not of standard quality report of any drug pertaining to this Registration Certificate declared by the Regulatory Authority of the country of origin or by any Regulatory Authority of any other country, where the drug is marketed/sold or distributed. The despatch and marketing of the drug in such cases shall be stopped immediately, and the licensing authority shall be informed immediately. Further action in respect of such stopped marketing of drug shall be followed as per the direction of the licensing authority. In such cases, action equivalent to that taken with reference to the concerned drug in the country of origin or in the country of marketing shall be followed in India also, in consultation with the licensing authority. The licensing authority may, however, direct any further modification to this course of action, including the withdrawal of the drug from Indian market within 48 hours time period.
5. The manufacturer or his authorised agent in India shall inform the licensing authority within 30 days in writing in the event of any change in manufacturing process, or in packaging, or in labelling or in testing, or in documentation of any of the drug pertaining to this Registration Certificate. In such cases, where there shall be any major change/modification in manufacturing, or in processing or in testing, or in documentation as the case may be, at the discretion of the licensing authority, the manufacturer or his authorised agent in India shall obtain necessary approval within 30 days by submitting a separate application along with the registration fee, as specified in clause (ii) of sub rule (3) of rule 24-A.
6. The manufacturer or his authorised agent in India shall inform the licensing authority immediately in writing in the event of any change in the constitution of the firm and /or address of the registered office/ factory premises operating under this Registration Certificate. Where any such change in the constitution of the firm and/or address takes place, the current Registration Certificate shall be deemed to be valid for a maximum period of three months from the date on which the change has taken place unless, in the meantime, a fresh Registration Certificate has been taken from the licensing authority in the name of the firm with the changed constitution of the firm and/or changed address of the registered office or factory premises".




GOVERNMENT OF INDIA

Central Drugs Standard Control Organisation
Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)

NAME (S) OF DRUGS, WHICH MAY BE IMPORTED
UNDER REGISTRATION CERTIFICATE NO. BD-488
DATED



Place: New Delhi

Date: 18 AUG 2011



LICENSING AUTHORITY

डा. सुरिन्द्र सिंह/Stamp
Dr. SURINDER SINGH
औषधि नियंत्रक (भारत)/Drugs Controller (India)
स्वास्थ्य सेवा महानिदेशालय
Dte. General of Health Services
FDA Bhawan, Kotla Road,
New Delhi-110002



From :
The Drugs Controller General (India)
Directorate General of Health Services

FDA Bhawan, New Delhi
Dated

18 AUG 2011

To,

M/S. NOVARTIS HEALTHCARE PVT LTD
GALA NO.1 -A &2-A,BLDG NO.28
ARIHANT COMPLEX KOPAR, PURNA TAL
BHIWANDI
DISTRICT MAHARSHTRA

Sub: -Registration of M/S. LABORATORIES THISEN S.A RUE DE LA POPYREE 4-6
1420 BRAIN L-ALLUED, BELGIUM under the Provisions of Drug & Cosmetics
Rules for the purpose of import of drugs in India

Dear Sir,

Please refer to your application no. NIL dated 30/05/2011, received by this Office vide diary no. 25556 dated 30/05/2011 on the above subject. Registration Certificate in Form 41 under the Rules is issued for the manufacturing site along with the name (s) of drug (s) imported under the said Certificate subject to the condition:


1. The drugs shall confirm to the standards / specifications mentioned in the Second Schedule of the Act, or such other standards / specifications forwarded by you and approved by this Directorate.
2. The drugs shall have the composition, strengths, standards and packing as approved by this Directorate.
3. Dispute, if any, in respect of the payment of fees and submission of TR6 challan, shall have to be settled between the bank and the applicant.
4. The drugs will be required to be withdrawn from sale from the market in case any undesirable reactions due to its medication are brought to light at any stage. This Directorate should be informed of adverse reports on the drug, if any.
5. The drugs shall be marketed for indications for which they have been approved.
6. If any claim is made for these drugs in future other than those approved, prior permissions from this Directorate will be necessary before such claim is made.
7. The drugs shall be supplied and marketed as per the provisions of the existing Drugs & Cosmetics Act and Rules thereunder.

8. This registration in no way relieves you of the responsibility of complying with all other provisions of the Drugs & Cosmetics Act and Rules there under, and any other provisions of any other Act and Rules applicable in the matter concerned.
9. Each consignment of the drugs to be imported by you shall be accompanied by a test / analysis reports.
10. Based on this registration, import applications for the drug (s) endorsed in the enclosed Registration Certificate shall be considered for the issue of Form 10 Licence under the Rules.
11. This Registration Certificate is being issued under the condition that during the pendency of Registration, the applicant may be required to deposit inspection fee as stipulated under Clause (5) of Rule 24-A and enable inspection of manufacturing site by the officials authorised for this purpose. Non-compliance to this condition as and when so directed would result in cancellation of Registration Certification.
12. ANNUAL PRODUCT REVIEW DATA OF TWO YEARS BY MANUFACTURER SHALL BE SUBMITTED WITHIN 45 DAYS FROM ISSUE DATE OF RC.
13. POA SIGNED BY INDIAN AGENT AS WELL AS MANUFACTURER AUTHENTICATED BY INDIAN EMBASSY SHAL BE SUBMITTED TO THIS OFFICE BEFORE IMPORT OF DRUG.
14. ORIGINAL LABEL OF THE DRUG AS GIVEN IN RC ALONG WITH PACKAGE INSERT SHALL BE SUBMITTED TO THIS OFFICE BEFORE IMPORT OF DRUG.

Please note that Registration Certificate issued is liable to be suspended / cancelled, if any of the condition stipulated above is not complied with, apart from any other condition that may be taken under the provisions of the Drugs & Cosmetics Act, 1940 and the Rules there under.


Please acknowledge the receipt.

Yours faithfully,


Drugs Controller General (India)

Copy forwarded to:

1. The Assistant Drug Controller (I), New Custom House, Annexe, Ballard Estate, Fort, Mumbai-400038.
2. The Assistant Drug Controller (I), 15/1, Strand Road, Custom House, Kolkata-700001.
3. The Assistant Drug Controller (I), Room No. 66, 2nd Floor, Custom House, Chennai-600001.
4. The Assistant Drug Controller (I), Jawaharlal Nehru Port, Trust Nhava Seva Port, Raigard, Maharashtra.
5. The Assistant Drug Controller (I), International Air Cargo Complex, Indira Gandhi International Air Port, New Delhi-110037.



सत्यमेव जयते

GOVERNMENT OF INDIA

Central Drugs Standard Control Organisation Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)

Form 41

(See Rule 27-A)

REGISTRATION CERTIFICATE

Registration Certificate issued for import of drugs into India

Under Drugs and Cosmetics Rules, 1945

Registration Certificate No. FF-595

Dated 18 AUG 2011

1. M/S. LABORATORIES THISSEN S.A RUE DE LA POPYREE 4-6 ,1420 BRAIN L-ALLUED, BELGIUM having factory premises at M/s. LABORATORIES THISSEN S.A RUE DE LA POPYREE 4-6 ,1420 BRAIN L-ALLUED, BELGIUM has been registered under Rule 27-A as a manufacturer and is hereby issued this Registration Certificate.
2. Name(s) of drug(s) which may be imported under this Registration Certificate (Please refer the enclosed list of drugs).
3. This Registration Certificate shall be in force from 01/06/2011 to 31/05/2014 unless it is sooner suspended or cancelled under the rules.
4. This Registration Certificate is issued through the office of the manufacturer or his authorised agent in India M/S NOVARTIS HEALTHCARE RVT LTD GALA NO.1 -A & 2-A, BLDG NO.28 ARIHANT COMPLEX KOPAR, PURNA TAL BHIWANDI DISTRICT MAHARSHTRA who will be responsible for the business activities of the manufacturer in India in all respects.
5. This Registration Certificate is subject to the conditions stated overleaf and to such other conditions as may be specified in the Act and the Rules, from time to time.

Place: New Delhi

Date: 18 AUG 2011



LICENSING AUTHORITY

डा. सुरिन्द्र सिंह
Dr. SURINDER SINGH
लौकिक नियंत्रक (भारत) / Drugs Controller (India)
स्वास्थ्य सेवा महानिदेशालय
Dte. General of Health Services
FDA Bhawan, Kolla Road,
New Delhi-110002

Conditions of the Registration Certificate

1. The Registration Certificate shall be displayed at a prominent place by the authorised agent.
2. No drug shall be registered unless it has a free sale approval in the country of origin, and/or in other major countries.
3. The manufacturer or his authorised agent in India shall comply with the conditions of the import licence issued under the Drugs and Cosmetics Rules, 1945.
4. The manufacturer or his authorised agent in India shall inform the licensing authority forthwith in the event of any administrative action taken due to adverse reaction, viz. market withdrawal, regulatory restrictions, or cancellation of authorisation, and/or not of standard quality report of any drug pertaining to this Registration Certificate declared by the Regulatory Authority of the country of origin or by any Regulatory Authority of any other country, where the drug is marketed/sold or distributed. The despatch and marketing of the drug in such cases shall be stopped immediately, and the licensing authority shall be informed immediately. Further action in respect of such stopped marketing of drug shall be followed as per the direction of the licensing authority. In such cases, action equivalent to that taken with reference to the concerned drug in the country of origin or in the country of marketing shall be followed in India also, in consultation with the licensing authority. The licensing authority may, however, direct any further modification to this course of action, including the withdrawal of the drug from Indian market within 48 hours time period.
5. The manufacturer or his authorised agent in India shall inform the licensing authority within 30 days in writing in the event of any change in manufacturing process, or in packaging, or in labelling or in testing, or in documentation of any of the drug pertaining to this Registration Certificate. In such cases, where there shall be any major change/modification in manufacturing, or in processing or in testing, or in documentation as the case may be, at the discretion of the licensing authority, the manufacturer or his authorised agent in India shall obtain necessary approval within 30 days by submitting a separate application along with the registration fee, as specified in clause (ii) of sub rule (3) of rule 24-A.
6. The manufacturer or his authorised agent in India shall inform the licensing authority immediately in writing in the event of any change in the constitution of the firm and /or address of the registered office/ factory premises operating under this Registration Certificate. Where any such change in the constitution of the firm and/or address takes place, the current Registration Certificate shall be deemed to be valid for a maximum period of three months from the date on which the change has taken place unless, in the meantime, a fresh Registration Certificate has been taken from the licensing authority in the name of the firm with the changed constitution of the firm and/or changed address of the registered office or factory premises".



सत्यमेव जयते


GOVERNMENT OF INDIA

Central Drugs Standard Control Organisation
Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)

NAME (S) OF DRUGS, WHICH MAY BE IMPORTED
UNDER REGISTRATION CERTIFICATE NO. FF-595
DATED **18 AUG. 2011**

CARDIOXANE INJECTION CONTAINING DEXRAZAXONE
500MG POWDER (LYOPHILISED) FOR INTRAVENOUS
INFUSION



Place: New Delhi

Date: **18 AUG. 2011**



LICENSING AUTHORITY

डा. सुरिन्द्र सिंह Seal/Stamp
Dr. SURINDER SINGH
औषधि नियंत्रक (भारत)/Drugs Controller (India)
स्वास्थ्य सेवा महानिदेशालय
Dts. General of Health Services
FDA Bhawan, Kotta Road,
New Delhi-110002

11-2-1971

No. 6-4/FF/119/02-DC(REREG2008) (ENDORSEMENT)

From :
The Drugs Controller General (India)
Directorate General of Health Services

FDA Bhawan, New Delhi
Dated

18 AUG 2011

To,

M/S. JOHNSON & JOHNSON LIMITED
6B, SHANTINAGAR INDUSTRIAL ESATATE,
VAKOLA SANTACRUZ(E)
MUMBAI-400055

Sub: -Registration of M/S. JANSSEN PHARMACEUTICA NV JANSSEN PHARMACEUTICA NV, TURNHOUTSEWEG 30, B-2340 BEERSE, BELGIUM under the Provisions of Drug & Cosmetics Rules for the purpose of import of drugs in India

Dear Sir,

Please refer to your application No. NIL dated 04/07/2011: received by this Office vide diary No: 32133 dated: 05/07/2011 on the above subject. Registration Certificate in Form 41 under the Rules is issued for the manufacturing site along with the name (s) of drug (s) imported under the said Certificate subject to the condition:

1. The drugs shall confirm to the standards / specifications mentioned in the Second Schedule of the Act, or such other standards / specifications forwarded by you and approved by this Directorate.
2. The drugs shall have the composition, strengths, standards and packing as approved by this Directorate.
3. Dispute, if any, in respect of the payment of fees and submission of TR6 challan, shall have to be settled between the bank and the applicant.
4. The drugs will be required to be withdrawn from sale from the market in case any undesirable reactions due to its medication are brought to light at any stage. This Directorate should be informed of adverse reports on the drug, if any.
5. The drugs shall be marketed for indications for which they have been approved.
6. If any claim is made for these drugs in future other than those approved, prior permissions from this Directorate will be necessary before such claim is made.
7. The drugs shall be supplied and marketed as per the provisions of the existing Drugs & Cosmetics Act and Rules thereunder.

- 8 This registration in no way relieves you of the responsibility of complying with all other provisions of the Drugs & Cosmetics Act and Rules there under, and any other provisions of any other Act and Rules applicable in the matter concerned.
- 9 Each consignment of the drugs to be imported by you shall be accompanied by a test / analysis reports.
- 10 Based on this registration, import applications for the drug (s) endorsed in the enclosed Registration Certificate shall be considered for the issue of Form 10 Licence under the Rules.
- 11 This Registration Certificate is being issued under the condition that during the pendency of Registration, the applicant may be required to deposit inspection fee as stipulated under Clause (5) of Rule 24-A and enable inspection of manufacturing site by the officials authorised for this purpose. Non-compliance to this condition as and when so directed would result in cancellation of Registration Certification.
- 12 ANNUAL PRODUCT REVIEW DATA OF LAST TWO YEARS SHALL BE SUBMITTED TO THIS OFFICE.
- 13 ORIGINAL LABEL OF THE DRUG ALONG WITH PACKAGE INSERT OF EACH STRENGTH SHALL BE SUBMITTED TO THIS OFFICE BEFORE IMPORT OF DRUG.

Please note that Registration Certificate issued is liable to be suspended / cancelled, if any of the condition stipulated above is not complied with, apart from any other condition that may be taken under the provisions of the Drugs & Cosmetics Act, 1940 and the Rules there under.

Please acknowledge the receipt.

Yours faithfully,

Drugs Controller General (India)

Copy forwarded to:

1. The Assistant Drug Controller (I), New Custom House, Annexe, Ballard Estate, Fort, Mumbai-400038.
2. The Assistant Drug Controller (I), 15/1, Strand Road, Custom House, Kolkata-700001.
3. The Assistant Drug Controller (I), Room No. 66, 2nd Floor, Custom House, Chennai-600001.
4. The Assistant Drug Controller (I), Jawaharlal Nehru Port, Trust Nhava Seva Port, Raigard, Maharashtra.
5. The Assistant Drug Controller (I), International Air Cargo Complex, Indira Gandhi International Air Port, New Delhi-110037.

GOVERNMENT OF INDIA



Central Drugs Standard Control Organisation
Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)

सत्यमेव जयते

NAME (S) OF DRUGS, WHICH MAY BE IMPORTED
UNDER REGISTRATION CERTIFICATE NO. FF -116
DATED 26/11/2008 VALID UPTO 31/12/2011

ENDORSEMENT No. 1

*PALIPERIDONE PALMITATE PROLONGED RELEASE
SUSPENSION FOR INJECTION

EACH PRE-FILLED SYRINGE OF 0.25ML/0.5ML/0.75ML/1ML
CONTAINS:-
PALIPERIDONE PALMITATE EQUIV TO PALIPERIDONE...
25/50/75/100 MG

ITEMS (ONE) ONLY

*COPY OF RULE 122 A PERMISSION SHALL BE SUBMITTED TO THIS
OFFICE AT THE TIME OF APPLICATION OF FORM TEN.

Place: New Delhi

Date: 18 AUG 2011



LICENSING AUTHORITY

डा. सुरिन्द्र सिंह Seal/Stamp
Dr. SURINDER SINGH
औद्योगिक नियंत्रक (भारत) / Drugs Controller (India)
स्वास्थ्य सेवा महानिदेशालय
Dte. General of Health Services
FDA Bhawan, Koka Road,
New Delhi-110002

From :
The Drugs Controller General (India)
Directorate General of Health Services

FDA Bhawan, New Delhi
Dated.

18 AUG 2011

To,

M/S. WYETH LIMITED,
LEVEL 6 PLATINA, PLOT NO C-59, 'G'
BLOCK, BANDRA (E), BANDRA - KURLA
COMPLEX
MUMBAI - 400098

Sub: -Registration of M/S. WYETH PARENTERALS, DIVISION OF WYETH HOLDINGS CORPORATION, 65 TH INFANTRY AVENUE, KILOMETER 9.7, CAROLINA PUERTO RICO under the Provisions of Drug & Cosmetics Rules for the purpose of import of drugs in India

Dear Sir,

Please refer to your application no. NIL dated 11/07/2011, received by this Office vide diary no. 33164 dated 12/07/2011 on the above subject. Registration Certificate in Form 41 under the Rules is issued for the manufacturing site along with the name (s) of drug (s) imported under the said Certificate subject to the condition:

1. The drugs shall confirm to the standards / specifications mentioned in the Second Schedule of the Act, or such other standards / specifications forwarded by you and approved by this Directorate.
2. The drugs shall have the composition, strengths, standards and packing as approved by this Directorate.
3. Dispute, if any, in respect of the payment of fees and submission of TR6 challan, shall have to be settled between the bank and the applicant.
4. The drugs will be required to be withdrawn from sale from the market in case any undesirable reactions due to its medication are brought to light at any stage. This Directorate should be informed of adverse reports on the drug, if any.
5. The drugs shall be marketed for indications for which they have been approved.
6. If any claim is made for these drugs in future other than those approved, prior permissions from this Directorate will be necessary before such claim is made.
7. The drugs shall be supplied and marketed as per the provisions of the existing Drugs & Cosmetics Act and Rules thereunder.

8. This registration in no way relieves you of the responsibility of complying with all other provisions of the Drugs & Cosmetics Act and Rules there under, and any other provisions of any other Act and Rules applicable in the matter concerned.
9. Each consignment of the drugs to be imported by you shall be accompanied by a test / analysis reports.
10. Based on this registration, import applications for the drug (s) endorsed in the enclosed Registration Certificate shall be considered for the issue of Form 10 Licence under the Rules.
11. This Registration Certificate is being issued under the condition that during the pendency of Registration, the applicant may be required to deposit inspection fee as stipulated under Clause (5) of Rule 24-A and enable inspection of manufacturing site by the officials authorised for this purpose. Non-compliance to this condition as and when so directed would result in cancellation of Registration Certification.

Please note that Registration Certificate issued is liable to be suspended / cancelled, if any of the condition stipulated above is not complied with, apart from any other condition that may be taken under the provisions of the Drugs & Cosmetics Act, 1940 and the Rules there under.


Please acknowledge the receipt.

Yours faithfully,

Drugs Controller General (India)

Copy forwarded to:

1. The Assistant Drug Controller (I), New Custom House, Annexe, Ballard Estate, Fort, Mumbai-400038.
2. The Assistant Drug Controller (I), 15/1, Strand Road, Custom House, Kolkata-700001.
3. The Assistant Drug Controller (I), Room No. 66, 2nd Floor, Custom House, Chennai-600001.
4. The Assistant Drug Controller (I), Jawaharlal Nehru Port, Trust Nhava Seva Port, Raigard, Maharashtra.
5. The Assistant Drug Controller (I), International Air Cargo Complex, Indira Gandhi International Air Port, New Delhi-110037.



सत्यमेव जयते

GOVERNMENT OF INDIA

Central Drugs Standard Control Organisation Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)

Form 41

(See Rule 27-A)

REGISTRATION CERTIFICATE

Registration Certificate issued for import of drugs into India

Under Drugs and Cosmetics Rules, 1945

Registration Certificate No. FF-471

Dated

18 AUG 2011

1. M/S. WYETH PARENTERALS, DIVISION OF WYETH HOLDINGS CORPORATION, 65 TH INFANTRY AVENUE, KILOMETER 9.7, CAROLINA having factory premises at M/s. WYETH PARENTERALS, DIVISION OF WYETH HOLDINGS CORPORATION, 65 TH INFANTRY AVENUE, KILOMETER 9.7, CAROLINA PUERTO RICO has been registered under Rule 27-A as a manufacturer and is hereby issued this Registration Certificate.
2. Name(s) of drug(s), which may be imported under this Registration Certificate (Please refer the enclosed list of drugs).
3. This Registration Certificate shall be in force from 01/08/2011 to 31/07/2014 unless it is sooner suspended or cancelled under the rules.
4. This Registration Certificate is issued through the office of the manufacturer or his authorised agent in India M/S WYETH LIMITED, LEVEL 6 PLATINA, PLOT NO C-59, 'G' BLOCK, BANDRA (E), BANDRA - KURLA COMPLEX MUMBAI - 400098 who will be responsible for the business activities of the manufacturer in India in all respects.
5. This Registration Certificate is subject to the conditions stated overleaf and to such other conditions as may be specified in the Act and the Rules, from time to time.

Place: New Delhi

Date: _____

18 AUG 2011




LICENSING AUTHORITY

डा. सुरिंदर सिंह
Dr. SURINDER SINGH
औषधि नियंत्रक (भारत)/Drugs Controller (India)
स्वास्थ्य सेवा महानिदेशालय
Dte. General of Health Services
FDA Bhawan, Kotla Road,
New Delhi-110002

Conditions of the Registration Certificate

1. The Registration Certificate shall be displayed at a prominent place by the authorised agent.
2. No drug shall be registered unless it has a free sale approval in the country of origin, and/or in other major countries.
3. The manufacturer or his authorised agent in India shall comply with the conditions of the import licence issued under the Drugs and Cosmetics Rules, 1945.
4. The manufacturer or his authorised agent in India shall inform the licensing authority forthwith in the event of any administrative action taken due to adverse reaction, viz. market withdrawal, regulatory restrictions, or cancellation of authorisation, and/or not of standard quality report of any drug pertaining to this Registration Certificate declared by the Regulatory Authority of the country of origin or by any Regulatory Authority of any other country, where the drug is marketed/sold or distributed. The despatch and marketing of the drug in such cases shall be stopped immediately, and the licensing authority shall be informed immediately. Further action in respect of such stopped marketing of drug shall be followed as per the direction of the licensing authority. In such cases, action equivalent to that taken with reference to the concerned drug in the country of origin or in the country of marketing shall be followed in India also, in consultation with the licensing authority. The licensing authority may, however, direct any further modification to this course of action, including the withdrawal of the drug from Indian market within 48 hours time period.
5. The manufacturer or his authorised agent in India shall inform the licensing authority within 30 days in writing in the event of any change in manufacturing process, or in packaging, or in labelling or in testing, or in documentation of any of the drug pertaining to this Registration Certificate. In such cases, where there shall be any major change/modification in manufacturing, or in processing or in testing, or in documentation as the case may be, at the discretion of the licensing authority, the manufacturer or his authorised agent in India shall obtain necessary approval within 30 days by submitting a separate application along with the registration fee, as specified in clause (ii) of sub rule (3) of rule 24-A.
6. The manufacturer or his authorised agent in India shall inform the licensing authority immediately in writing in the event of any change in the constitution of the firm and /or address of the registered office/ factory premises operating under this Registration Certificate. Where any such change in the constitution of the firm and/or address takes place, the current Registration Certificate shall be deemed to be valid for a maximum period of three months from the date on which the change has taken place unless, in the meantime, a fresh Registration Certificate has been taken from the licensing authority in the name of the firm with the changed constitution of the firm and/or changed address of the registered office or factory premises".



सत्यमेव जयते

GOVERNMENT OF INDIA

Central Drugs Standard Control Organisation
Ministry of Health & Family Welfare

FDA BHAWAN, NEW DELHI (INDIA)

NAME (S) OF DRUGS, WHICH MAY BE IMPORTED
UNDER REGISTRATION CERTIFICATE NO. FF-471
DATED **18 AUG 2011**

TIGECYCLINE (LYOPHILIZED POWDER FOR INJECTION),
50MG
EACH VIAL CONTAINS :TIGECYCLINE 50MG

OFFICE COPY

ITEMS (ONE) ONLY

Place: New Delhi

Date: **18 AUG 2011**




LICENSING AUTHORITY

डा. सुरिन्द्र सिंह/Stamp
Dr. SURINDER SINGH
औषधि नियंत्रक (भारत)/Drugs Controller (India)
स्वास्थ्य सेवा महानिदेशालय
Dte. General of Health Services
FDA Bhawan, Kotla Road,
New Delhi-110002

